Ortho Clinical Diagnostics (NASDAQ: OCDX) is one of 36 public companies in the “Diagnostic substances” industry, but how does it contrast to its competitors? We will compare Ortho Clinical Diagnostics to similar companies based on the strength of its valuation, dividends, institutional ownership, profitability, earnings, analyst recommendations and risk.
Institutional and Insider Ownership
52.9% of shares of all “Diagnostic substances” companies are owned by institutional investors. 7.5% of shares of all “Diagnostic substances” companies are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
This is a breakdown of recent recommendations and price targets for Ortho Clinical Diagnostics and its competitors, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Ortho Clinical Diagnostics||0||1||11||0||2.92|
|Ortho Clinical Diagnostics Competitors||179||664||1087||34||2.50|
Ortho Clinical Diagnostics currently has a consensus target price of $24.55, indicating a potential upside of 12.18%. As a group, “Diagnostic substances” companies have a potential upside of 0.40%. Given Ortho Clinical Diagnostics’ stronger consensus rating and higher possible upside, equities research analysts plainly believe Ortho Clinical Diagnostics is more favorable than its competitors.
Earnings & Valuation
This table compares Ortho Clinical Diagnostics and its competitors revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Ortho Clinical Diagnostics||$1.77 billion||-$211.90 million||75.21|
|Ortho Clinical Diagnostics Competitors||$405.90 million||$35.95 million||-56.54|
Ortho Clinical Diagnostics has higher revenue, but lower earnings than its competitors. Ortho Clinical Diagnostics is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.
This table compares Ortho Clinical Diagnostics and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Ortho Clinical Diagnostics||N/A||N/A||N/A|
|Ortho Clinical Diagnostics Competitors||-3,099.44%||-696.75%||-183.84%|
Ortho Clinical Diagnostics beats its competitors on 8 of the 12 factors compared.
About Ortho Clinical Diagnostics
Ortho Clinical Diagnostics Holdings plc engages in the vitro diagnostics business worldwide. The company offers automated instruments; and assays, reagents, and other consumables that are used by these instruments to generate test results. Its solutions include clinical chemistry and immunoassay instruments and tests to detect and monitor disease progression across a spectrum of therapeutic areas, including COVID-19 antibody and antigen tests; and immunohematology instruments and tests for blood typing to ensure patient-donor compatibility in blood transfusions, as well as donor screening instruments and tests for blood and plasma screening for infectious diseases. The company also engages in contract manufacturing activities; and provides orthocare services. Its products are used in hospitals, laboratories, clinics, blood banks, and donor centers. The company was founded in 1939 and is headquartered in Raritan, New Jersey.
Receive News & Ratings for Ortho Clinical Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ortho Clinical Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.